No link between short-term testosterone use and prostate cancer, study says
Testosterone therapy does not cause adverse effects on the prostate in older men with hypogonadism, commonly known as low testosterone or low T, according to a clinical trial presented today at a national urology meeting in Atlanta. The study, which focused on direct measurement of testosterone in prostate tissues, carries important implications for the millions of men with low testosterone, who may benefit from testosterone replacement therapy. Results from the study were presented in two abstracts at the American Urological Association annual meeting.
"We found no evidence that testosterone replacement therapy negatively affects the prostate or its tissues in hypogonadal men following six months of treatment," said Dr. Leonard Marks, co-investigator, Clinical Associate Professor in the Department of Surgery/Urology at the UCLA School of Medicine and founding medical director of Urological Sciences Research Foundation (USRF). "Patients should be comforted by these results, but large-scale, long-term trials are still needed."
Testosterone is a hormone involved in regulating prostate growth, both benign and malignant. When testosterone is boosted, the effect on the prostate is a main concern in older men. However, this study showed that when serum testosterone levels are increased to the mid-normal level, the prostate effects are minimal, at 6-months.
In the randomized, placebo-controlled clinical trial, investigators examined the effects of testosterone (T) in 41 men, ages 50-75 years old with hypogonadism (ADAM score and morning T<300 ng/dL) for a 6-month period. Twenty-one men received testosterone intramuscular injections (150 mg every two weeks); 20 men received placebo. The study was powered to detect a 25% increase in dihydrotestosterone (DHT) in prostate tissue. The groups were comparable at baseline for age, serum T and DHT, Prostate-Specific Antigen (PSA), Prostate Volume (PV) and median prostate levels of T and DHT. Prostate biopsies were conducted at baseline and at 6-months.
No prostate tissue changes attributable to testosterone therapy were found in this trial. Despite marked increases in serum testosterone levels, prostate levels of T and DHT (the hormone that stimulates prostate gland growth) did not change from baseline at 6-months. PSA, PV, tissue biomarkers and indices for atrophy and inflammation also were unchanged after 6-months of treatment. Furthermore, gene expression was not altered, cell proliferation was not accelerated, and histologic cancers were not increased. The study also showed testosterone therapy created positive effects in bones and muscles.
"The prostate appears to be buffered against rather wide fluctuations in serum testosterone levels," said Dr. Marks. "Still, all hypogonadal men considering testosterone therapy, especially older men, must be monitored closely by their physicians prior to and throughout treatment."
Dr. Leonard Marks | EurekAlert!
The most recent press releases about innovation >>>
Die letzten 5 Focus-News des innovations-reports im Überblick:
Whether you call it effervescent, fizzy, or sparkling, carbonated water is making a comeback as a beverage. Aside from quenching thirst, researchers at the University of Illinois at Urbana-Champaign have discovered a new use for these "bubbly" concoctions that will have major impact on the manufacturer of the world's thinnest, flattest, and one most useful materials -- graphene.
As graphene's popularity grows as an advanced "wonder" material, the speed and quality at which it can be manufactured will be paramount. With that in mind,...
Physicists at the University of Bonn have managed to create optical hollows and more complex patterns into which the light of a Bose-Einstein condensate flows. The creation of such highly low-loss structures for light is a prerequisite for complex light circuits, such as for quantum information processing for a new generation of computers. The researchers are now presenting their results in the journal Nature Photonics.
Light particles (photons) occur as tiny, indivisible portions. Many thousands of these light portions can be merged to form a single super-photon if they are...
For the first time, scientists have shown that circular RNA is linked to brain function. When a RNA molecule called Cdr1as was deleted from the genome of mice, the animals had problems filtering out unnecessary information – like patients suffering from neuropsychiatric disorders.
While hundreds of circular RNAs (circRNAs) are abundant in mammalian brains, one big question has remained unanswered: What are they actually good for? In the...
An experimental small satellite has successfully collected and delivered data on a key measurement for predicting changes in Earth's climate.
The Radiometer Assessment using Vertically Aligned Nanotubes (RAVAN) CubeSat was launched into low-Earth orbit on Nov. 11, 2016, in order to test new...
A study led by scientists of the Max Planck Institute for the Structure and Dynamics of Matter (MPSD) at the Center for Free-Electron Laser Science in Hamburg presents evidence of the coexistence of superconductivity and “charge-density-waves” in compounds of the poorly-studied family of bismuthates. This observation opens up new perspectives for a deeper understanding of the phenomenon of high-temperature superconductivity, a topic which is at the core of condensed matter research since more than 30 years. The paper by Nicoletti et al has been published in the PNAS.
Since the beginning of the 20th century, superconductivity had been observed in some metals at temperatures only a few degrees above the absolute zero (minus...